What is IMDX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.11B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IMDX?

P/E (TTM) is n/a and 52-week range is $2.42 to $8.51 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IMDX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IMDX?

The company profile lists revenue (TTM) near $1M, net income (TTM) near $-4.33B, EPS (TTM) near $-1.48 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Insight Molecular Diagnostics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Nashville, Tennessee, US, 32.3M shares outstanding, ISIN US68235C2061 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Insight Molecular Diagnostics Inc

$IMDX

Health Care · Biotechnology

IR Run Scenarios

$3.37

+2.74%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Insight Molecular Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Nashville, Tennessee and currently employs 55 full-time employees. The company went IPO on 2015-12-30. The firm's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The firm's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.

Employees

Website

imdxinc.com/

IPO

2015-12-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)